Exenatide was the first GLP-1 receptor agonist approved, derived from a compound in Gila monster saliva; semaglutide is a modern, far more potent successor. Comparing them is essentially comparing the start and the current peak of the GLP-1 era — newer chemistry delivers greater weight loss, better glucose control, and more convenient dosing.
At a glance
| Semaglutide | Exenatide | |
|---|---|---|
| Drug class | GLP-1 receptor agonist | GLP-1 receptor agonist (exendin-4 based) |
| Brand names | Ozempic, Wegovy, Rybelsus | Byetta, Bydureon |
| FDA status | Approved | Approved (earlier generation) |
| Dosing | Once weekly (plus daily oral) | Twice daily (Byetta) or weekly (Bydureon) |
| Weight loss | Greater | More modest |
| Generation | Modern | First-generation GLP-1 |
| Main side effects | GI: nausea, diarrhea | GI: nausea; injection-site nodules (Bydureon) |
The bottom line
Bottom line: Semaglutide is the more potent, more convenient modern drug, with greater weight loss and glucose lowering than first-generation exenatide. Exenatide is historically important and still used, but newer agents have largely surpassed it. Both are approved prescription medicines.
Frequently asked questions
Is exenatide still used?
Exenatide is still available but has been largely overtaken by newer, more potent GLP-1 agonists like semaglutide and dual agonists like tirzepatide, which offer greater weight loss and more convenient dosing.
What makes exenatide different?
Exenatide was the first GLP-1 receptor agonist approved and is based on exendin-4, a compound originally found in Gila monster saliva. Semaglutide is a later, human-GLP-1-based agent engineered for greater potency and longer action.
Which causes more weight loss?
Semaglutide produces greater average weight loss than exenatide in trials. Both are prescription GLP-1 medicines used under medical supervision.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. Peer-reviewed study
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023. Peer-reviewed study
- Chao AM, Tronieri JS, Amaro A, et al. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023. Peer-reviewed study
- Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021. Peer-reviewed study
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021. Peer-reviewed study
- Tan HC, Dampil OA, Marquez MM. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J ASEAN Fed Endocr Soc. 2022. Peer-reviewed study
- Parkes DG, Mace KF, Trautmann ME. Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone GLP-1. Expert Opin Drug Discov. 2013. Peer-reviewed study
- Briones M, Bajaj M. Exenatide: a GLP-1 receptor agonist as novel therapy for type 2 diabetes mellitus. Expert Opin Pharmacother. 2006. Peer-reviewed study
- Bray GM. Exenatide. Am J Health Syst Pharm. 2006. Peer-reviewed study
- Barnett AH. Exenatide. Drugs Today (Barc). 2005. Peer-reviewed study
- Barnett A. Exenatide. Expert Opin Pharmacother. 2007. Peer-reviewed study
- Mullins RJ, Mustapic M, Chia CW, et al. A Pilot Study of Exenatide Actions in Alzheimer's Disease. Curr Alzheimer Res. 2019. Peer-reviewed study